Optimized H7N9 induces higher Ab in humanized, but not standard, mice

  A new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than vaccines developed for … Continue reading

Posted in Blog, Featured, News | Tagged , , , , , , , , , , , | Leave a comment

Fearless Science at BIO2017

EpiVax will be in San Diego at the BIO international Convention, the most influential biotech convention in the industry. Look for us in the partnering system to arrange a meeting! After hours, we are hosting a networking reception at Puesto (Tuesday 20th, 7:00pm-9:30pm). Come unwind with … Continue reading

Posted in Blog, Events, Featured | Leave a comment

Happy Birthday EpiVax! We’re Celebrating With a New Look!

19 years ago EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of … Continue reading

Posted in Blog, Featured, News | Leave a comment

Tregitope Takes a Step Toward the Clinic

EpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced T·rej·itopes, are a … Continue reading

Posted in Featured, News | Tagged , , , , , , , , , , , | Leave a comment

Spring Is Here and EpiVax is Improving Human Health Everywhere

Those of us on the U.S. East Coast are happy to say farewell to winter – Spring is Here! And EpiVax is springing up everywhere! Join us at the following events to learn more about immunogenicity, influenza vaccines, personalized cancer … Continue reading

Posted in Events, Featured | Leave a comment

BARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?

“Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While mutations that would enable … Continue reading

Posted in Blog, Featured, News | Tagged , , , , , , , , , , , | Leave a comment

Our Prediction for 2017: Out with Post Hoc and Go DeFT! 

It’s a new year and welcome to it! Pundits are making a lot of predictions about the decline of science and technology under the new administration in Washington DC, and I’m here with a contrarian view. We bet on biotechnology! We predict … Continue reading

Posted in Blog, Featured, News | Tagged , , , , , , | Leave a comment

Update: Screening for Immunogenicity: Immunotherapy Challenges and Predictive Approaches Applied to Therapeutic Proteins 

Update: This event has been cancelled by the organizers. Thank you for your interest. As an expert in immunogenicity screening, EpiVax’s CEO/CSO, Dr. Annie De Groot, will be conducting a training on state of the art methods of in silico and in … Continue reading

Posted in Events, Featured | Tagged , , , , , , , , , , , | Leave a comment
tularemia bacteria

$1.87M BioDefense Grant to EpiVax and CUBRC

CUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical … Continue reading

Posted in Featured, News | Tagged , , , , , , | Leave a comment

The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

Building on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing cancer/normal protein sets, identifying … Continue reading

Posted in Blog, EpiVax Immunoncology, Featured, News | Tagged , , , , , , , , , , , , | Leave a comment